实体瘤疗效评价标准
医学
液体活检
实体瘤
循环肿瘤DNA
活检
医学物理学
放射科
放射性武器
肿瘤科
进行性疾病
疾病
内科学
癌症
作者
Mohamed A. Gouda,Filip Janků,Adam Wahida,Lars Buschhorn,Andreas Schneeweiß,Nagla Abdel Karim,Diego Pérez,Marzia Del Re,Alessandro Russo,Giuseppe Curigliano,Christian Rolfo,Vivek Subbiah
标识
DOI:10.1016/j.annonc.2023.12.007
摘要
Current evaluation of treatment response in solid tumors depends on dynamic changes in tumor diameters as measured by imaging. However, these changes can only be detected when there are enough macroscopic changes in tumor volume, which limits the usability of radiological response criteria in evaluating earlier stages of disease response and necessitates much time to lapse for gross changes to be notable. One promising approach is to incorporate dynamic changes in circulating tumor DNA (ctDNA), which occur early in the course of therapy and can predict tumor responses weeks before gross size changes manifest. However, several issues need to be addressed before recommending the implementation of ctDNA response criteria in daily clinical practice such as clinical, biological, and regulatory challenges and, most importantly, the need to standardize/harmonize detection methods and ways to define ctDNA response and/or progression for precision oncology. Herein, we review the use of liquid biopsy to evaluate response in solid tumors and propose a plan towards standardization of Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST)
科研通智能强力驱动
Strongly Powered by AbleSci AI